Home > Insider Trading > Filing (0001415889-24-024992)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Enliven Therapeutics Inc.	ELVN	Pharmaceutical Preparations (2834)	811523849

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1967150	P Joseph Lyssikatos	C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-10-08	13,167	$27.96	1,054,013	No	4	S	Indirect	See footnote
Common Stock	Disposition	2024-10-08	100	$28.51	1,053,913	No	4	S	Indirect	See footnote
Common Stock	Disposition	2024-10-09	34,289	$28.12	1,019,624	No	4	S	Indirect	See footnote
Common Stock	Disposition	2024-10-09	3,589	$28.52	1,016,035	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
This transaction was executed in multiple trades at prices ranging from $27.50 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
This transaction was executed in multiple trades at prices ranging from $27.50 to $28.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $28.50 to $28.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.